全文获取类型
收费全文 | 61670篇 |
免费 | 4238篇 |
国内免费 | 229篇 |
专业分类
耳鼻咽喉 | 748篇 |
儿科学 | 1580篇 |
妇产科学 | 1275篇 |
基础医学 | 7860篇 |
口腔科学 | 1004篇 |
临床医学 | 5935篇 |
内科学 | 12633篇 |
皮肤病学 | 834篇 |
神经病学 | 5937篇 |
特种医学 | 2086篇 |
外国民族医学 | 4篇 |
外科学 | 10307篇 |
综合类 | 834篇 |
现状与发展 | 1篇 |
一般理论 | 69篇 |
预防医学 | 5276篇 |
眼科学 | 1262篇 |
药学 | 3838篇 |
中国医学 | 62篇 |
肿瘤学 | 4592篇 |
出版年
2023年 | 225篇 |
2022年 | 448篇 |
2021年 | 1035篇 |
2020年 | 591篇 |
2019年 | 994篇 |
2018年 | 1203篇 |
2017年 | 844篇 |
2016年 | 952篇 |
2015年 | 1052篇 |
2014年 | 1725篇 |
2013年 | 2534篇 |
2012年 | 3714篇 |
2011年 | 4052篇 |
2010年 | 2308篇 |
2009年 | 2132篇 |
2008年 | 3674篇 |
2007年 | 3870篇 |
2006年 | 3845篇 |
2005年 | 3905篇 |
2004年 | 3844篇 |
2003年 | 3497篇 |
2002年 | 3437篇 |
2001年 | 611篇 |
2000年 | 536篇 |
1999年 | 691篇 |
1998年 | 793篇 |
1997年 | 693篇 |
1996年 | 618篇 |
1995年 | 580篇 |
1994年 | 507篇 |
1993年 | 476篇 |
1992年 | 461篇 |
1991年 | 457篇 |
1990年 | 382篇 |
1989年 | 378篇 |
1988年 | 343篇 |
1987年 | 319篇 |
1986年 | 304篇 |
1985年 | 364篇 |
1984年 | 506篇 |
1983年 | 455篇 |
1982年 | 543篇 |
1981年 | 538篇 |
1980年 | 517篇 |
1979年 | 291篇 |
1978年 | 318篇 |
1977年 | 311篇 |
1976年 | 242篇 |
1975年 | 240篇 |
1974年 | 259篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies
Bayard L. Powell Hyman B. Muss Robert L. Capizzi Mary E. Caponera Douglas R. White Patricia J. Zekan James N. Atkins Don V. Jackson Jr. Frederick Richards II John B. Craig Julia M. Cruz Charles L. Spurr 《Cancer chemotherapy and pharmacology》1987,19(3):250-252
Summary Cytosine arabinsodie (ara-C) and etoposide (VP-16) display synergy in the laboratory. Twenty-six patients participated in a phase I study of high-dose ara-C in combination with VP-16. The dose of VP-16 was held constant at 50 mg/m2 as an intermittent infusion over 33 h; escalating doses of ara-C were given as infusions during hours 9–12 and 21–24. Myelosuppression was the dose-limiting toxicity and occurred with doses considerably less than those expected from studies of the two drugs as single agents. The suggested initial doses for phase II trials with this schedule are 750 mg/m2×2 doses of ara-C and 50 mg/m2 of VP-16. Nonhematologic toxicity was minimal; therefore, further dose escalation is feasible in patients in whom myelosuppression is acceptable.Supported in part by grants from the National Cancer Institute (CA-12197 and CA-09422) and the American Cancer Society CF-85-182 相似文献
13.
J M Esteban J A Kuhn B Felder J Y Wong H Battifora J D Beatty P M Wanek J E Shively 《Cancer research》1991,51(14):3802-3806
We have previously shown that the colon carcinoma (LS174T) xenografts that emerged shortly after radioimmunotherapy with 90Y-labeled anti-CEA monoclonal antibody (MAb) ZCE025 lacked significant expression of CEA in comparison with the untreated tumors. The present study was designed to establish if the immunophenotype of the treated tumors was the result of CEA specific therapy and if the effect was permanent. Athymic mice bearing LS174T tumors were treated either with 120 mu Ci of 90Y-ZCE025, an equal dose of 90Y-96.5 (nonspecific MAb), or received no treatment. When the treated tumors grew to approximately 1.5 cm in diameter (6 weeks after therapy), they were resected and aliquoted to be transplanted to other mice, plated in tissue culture, fixed in formalin, and homogenized for CEA quantitation. The procedure was repeated 3 times (a total of 4 months after treatment). The CEA content was evaluated 2 and 6 weeks after therapy and when the tumors were transplanted. We confirmed a 4-fold decrease of CEA in the resurgent tumors 6 weeks after specific 90Y-ZCE025 therapy, which was twice the decrease experienced by the tumors treated with nonspecific 90Y-96.5, indicating substantial and specific killing of CEA-expressing cells. The CEA content slowly but progressively increased with each new pass of the tumor in the mice, reaching approximately one-half the value of the controls at the end of the study. The resurgent tumors were also studied by immunohistochemistry with MAbs detecting different epitopes of CEA, keratin, TAG-72, and epithelial membrane antigen to evaluate possible additional immunophenotypic changes induced by radioimmunotherapy. Only the expression of TAG-72 (recognized by MAb B72.3) increased immediately after therapy, but it returned to the original levels by the end of the study. These results suggest that: (a) specific radioimmunotherapy with 90Y-ZCE025 selectively kills cells that express higher levels of CEA; (b) the immunophenotype of the surviving fraction of the tumor appears to slowly revert to its original form; and (c) other tumor markers unrelated to CEA can also be affected. These observations have important implications for the design of radioimmunotherapy trials. 相似文献
15.
16.
Joseph F Malouf Manfredi Ballo Heidi M Connolly David O Hodge Regina M Herges Charles J Mullany Fletcher A Miller 《Journal of the American Society of Echocardiography》2005,18(3):252-256
The purpose of this study was to provide, in a large number of patients, comprehensive Doppler echocardiographic assessment of normal St Jude Medical mitral valve prosthesis function using Doppler-derived hemodynamic variables, including the mitral valve prosthesis-to-left ventricular outflow tract time-velocity integral ratio and prosthesis performance index. The pressure half-time was less than 130 milliseconds in all patients, and all but one patient had either a peak early mitral diastolic velocity of 2 m/s or less or a mitral valve prosthesis-to-left ventricular outflow tract time-velocity integral ratio of less than 2.2. There was a significant (P < .001) negative correlation between the prosthesis performance index and prosthesis size. This negative correlation suggests that there is more efficient use of the in vitro geometric orifice area with smaller prostheses. 相似文献
17.
18.
19.
20.
Charles Opondo Stephen Ntoburi John Wagai Jackline Wafula Aggrey Wasunna Fred Were Annah Wamae Santau Migiro Grace Irimu Mike English 《Tropical medicine & international health : TM & IH》2009,14(10):1165-1172
Objective To assess the availability of resources that support the provision of basic neonatal care in eight first‐referral level (district) hospitals in Kenya. Methods We selected two hospitals each from four of Kenya’s eight provinces with the aim of representing the diversity of this part of the health system in Kenya. We created a checklist of 53 indicator items necessary for providing essential basic care to newborns and assessed their availability at each of the eight hospitals by direct observation, and then compared our observations with the opinions of health workers providing care to newborns on recent availability for some items, using a self‐administered structured questionnaire. Results The hospitals surveyed were often unable to maintain a safe hygienic environment for patients and health care workers; staffing was insufficient and sometimes poorly organised to support the provision of care; some key equipment, laboratory tests, drugs and consumables were not available while patient management guidelines were missing in all sites. Conclusion Hospitals appear relatively poorly prepared to fill their proposed role in ensuring newborn survival. More effective interventions are needed to improve them to meet the special needs of this at‐risk group. 相似文献